SCHEMBL3603199

SCHEMBL3603199

CCOC(=O)N1CCN(C2Cc3ccc(N)cc3NC2=O)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.46
HPGD P15428 1/20 0.45
POLB P06746 2/20 0.43
SMN1; SMN2 Q16637 4/20 0.42
LMNA P02545 2/20 0.42
HTT P42858 1/20 0.42
GAA P10253 3/20 0.42
MAPT P10636 3/20 0.40
ABL1 P00519 1/20 0.40
RIN1 Q13671 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
CYP2C9 P11712 1/20 0.40
ALOX15 P16050 1/20 0.40
CYP2C19 P33261 1/20 0.40
RAB9A P51151 1/20 0.39
NPC1 O15118 1/20 0.39
ALOX12 P18054 1/20 0.39
DRD2 P14416 1/20 0.39
DRD4 P21917 1/20 0.39
TNF P01375 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3588944 0.81 DRD2 (0.44) ALDH1A1LMNAHTTGAAMAPT
SCHEMBL3597005 0.79 CA9 (0.45) ALDH1A1HPGDSMN1; SMN2LMNAHTT
SCHEMBL3600796 0.78 TSHR (0.46) ALDH1A1HPGDPOLBSMN1; SMN2LMNA
SCHEMBL3600127 0.77 CA9 (0.41) ALDH1A1LMNAHTTGAAMAPT
SCHEMBL3602310 0.77 CA9 (0.47) ALDH1A1LMNAHTTGAAMAPT
SCHEMBL3602346 0.77 CA9 (0.43) ALDH1A1SMN1; SMN2LMNAHTTGAA
SCHEMBL3595503 0.77 CA9 (0.39) ALDH1A1GAAMAPTTDP1ALOX15
SCHEMBL7828083 0.76 KMT2A (0.49) ALDH1A1HPGDSMN1; SMN2LMNAGAA
SCHEMBL3588009 0.76 CA9 (0.42) ALDH1A1SMN1; SMN2LMNAHTTGAA
SCHEMBL3583049 0.76 TRPV1 (0.48) ALDH1A1POLBSMN1; SMN2HTTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2010-01-21 US disclosed
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2010-01-21 US disclosed
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2010-01-21 US disclosed
EP-2128157-A1 HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2009-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE CCNY, CCND3, NSD3 ALDH1A1 1904/4885HPGD 2117/4885POLB 1341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.